Results 31 to 40 of about 135,031 (119)

HLA-DR Helps to Differentiate Erythrodermic Cutaneous T-cell Lymphoma from Erythrodermic Inflammatory Dermatoses in Flow Cytometry

Acta Dermato-Venereologica, 2023
Differential diagnosis of erythroderma is challenging in dermatology, especially in differentiating erythrodermic cutaneous T-cell lymphoma from erythrodermic inflammatory dermatoses.
Jingru Sun, Ran You, Beini Lyu, Xueying Li, Yumei Gao, Yujie Wen, Chenxue Qu, Yang Wang   +7 more
doaj   +1 more source

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study

eJHaem
Objective We report the results of a pilot study investigating the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed/ refractory T‐cell lymphoma. Methods A dose escalation study design was utilized.
Carrie van der Weyden, Mathias Bressel, Amit Khot, Henry Miles Prince, Michael Dickinson   +4 more
doaj   +1 more source

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma

Haematologica, 2011
We recently reported deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Functional analyses confirmed that PTPN2 acts as classical tumor suppressor repressing the proliferation of T cells, in part through ...
Maria Kleppe, Thomas Tousseyn, Eva Geissinger, Zeynep Kalender Atak, Stein Aerts, Andreas Rosenwald, Iwona Wlodarska, Jan Cools   +7 more
doaj   +1 more source

Peripheral T cell lymphoma: clinical utility of romidepsin

Blood and Lymphatic Cancer: Targets and Therapy, 2012
Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years.
Sawey K, Zain J
doaj  

Peripheral T-cell lymphoma, not otherwise specified

Journal of Family Medicine and Primary Care, 2017
The peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) belongs to a heterogeneous class of aggressive neoplasms. Although several morphologic subtypes of this tumor have been described, no particular genetic, immunological, or distinct ...
Kunal Kishor Jha, Suresh K Gupta, Harpreet Saluja, Nuwadatta Subedi   +3 more
doaj   +1 more source

Peripheral T Cell Non-Hodgkin’s Lymphoma following Treatment of Hodgkin’s Lymphoma

Case Reports in Oncological Medicine, 2015
Previous reports have suggested that non-Hodgkin’s lymphoma (NHL) is more likely to develop in patients with Hodgkin lymphoma (HL) compared to the general population. These two can occur synchronously or metachronously.
Sun Hee Chang, Hye Ran Lee
doaj   +1 more source

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

Leukemia Research Reports
Brentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV ...
Gen Hasegawa, Noriharu Nakagawa, Yoshimichi Ueda, Masahide Yamazaki   +3 more
doaj   +1 more source

Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified

Haematologica, 2018
Due to heterogeneous morphological and immunophenotypic features, approximately 50% of peripheral T-cell lymphomas are unclassifiable and categorized as peripheral T-cell lymphomas, not otherwise specified.
Meng-Meng Ji, Yao-Hui Huang, Jin-Yan Huang, Zhao-Fu Wang, Di Fu, Han Liu, Feng Liu, Christophe Leboeuf, Li Wang, Jing Ye, Yi-Ming Lu, Anne Janin, Shu Cheng, Wei-Li Zhao   +13 more
doaj   +1 more source

Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

BMC Cancer, 2019
Background Regulatory immune cells may modulate the lymphoma microenvironment and are of great interest due to the increasing prevalence of treatment with immunotherapies in lymphoma patients.
R-M Amini, G. Enblad, P. Hollander, S. Laszlo, E. Eriksson, K. Ayoola Gustafsson, A. Loskog, I. Thörn   +7 more
doaj   +1 more source

Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T‐cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report

Clinical Case Reports
Key Clinical Message Belinostat therapy followed by hematopoietic stem cell transplantation is a promising salvage strategy for heavily pretreated patients with peripheral T‐cell lymphoma.
Sigrid De Wilde, Carlos Graux
doaj   +1 more source